Understanding the immune system requires technologies capable of detecting a broad range of proteins with exceptional precision. The NULISAseq™ Immune 340 Panel is designed to support next-generation immune biomarker discovery by enabling researchers to measure approximately 340 immune-related proteins from a single plasma or serum sample. This comprehensive approach provides valuable insights into immune responses across various research applications.
NULISAseq™ Immune 340 Panel advances immune biomarker discovery with one of the most comprehensive immune profiling solutions available. Combining ~340 immune proteins with attomolar sensitivity, the panel delivers a broad view of the immune proteome from a single plasma or serum sample. Its ultra-sensitive detection capabilities help researchers identify low-abundance biomarkers that may be missed by conventional protein analysis methods, making it well suited for translational and clinical research.
Researchers working in immunology, oncology, autoimmune diseases, infectious diseases, and precision medicine increasingly rely on highly multiplexed proteomics platforms to better understand disease biology and therapeutic responses. By generating high-quality, reproducible protein measurements across hundreds of immune biomarkers, advanced multiplex assays support biomarker validation, longitudinal studies, and drug development programs.
If you are interested in learning more about the NULISAseq™ Immune 340 Panel, including its specifications, applications, and workflow, visit: NULISAseq™ Immune 340 Panel